Da Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Da Huang has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Yi Gao
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
20 shared publications - Chuanjie Zhang
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
18 shared publications - Chufeng Chen
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
18 shared publications - Dan-Feng Xu
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
18 shared publications - Hai Huang
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
18 shared publications - Hanqing Liu
Division of Life Sciences and Medicine, Department of Urology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China
18 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Assessment of pharmacological or toxicological effect of SKLB325 in treating PCa.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Assessment of pharmacological or toxicological effect of SKLB325 in treating PCa.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6/ATF4-sustained enhancer-promoter looping drives the transcription of glutathione biosynthesis pathway.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6/ATF4-sustained enhancer-promoter looping drives the transcription of glutathione biosynthesis pathway.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Identification of SPOP-JMJD6 regulating axis in PCa cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Identification of SPOP-JMJD6 regulating axis in PCa cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Characterization of JMJD6 clinical relevance in PCa samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Characterization of JMJD6 clinical relevance in PCa samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6-ATF4 complex regulates the ferroptosis susceptibility in PCa.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6-ATF4 complex regulates the ferroptosis susceptibility in PCa.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6 is important for SPOP-deficient PCa cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6 is important for SPOP-deficient PCa cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Oligonucleotides listed in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Oligonucleotides listed in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6 recruits Med1/14 to sustain enhancers activities.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6 recruits Med1/14 to sustain enhancers activities.
- Open Access
- 26 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e72597
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial
Background: Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD). Objective: We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas. Methods: We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group. Results: This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025. Conclusions: Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. Trial Registration: ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 International Registered Report Identifier (IRRID): DERR1-10.2196/72597
- 26 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e72597
Open AccessSurveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial
Background: Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD). Objective: We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas. Methods: We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group. Results: This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025. Conclusions: Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. Trial Registration: ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 International Registered Report Identifier (IRRID): DERR1-10.2196/72597
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Assessment of pharmacological or toxicological effect of SKLB325 in treating PCa.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Assessment of pharmacological or toxicological effect of SKLB325 in treating PCa.